Huntsman Cancer Institute Judson-Torres Lab

Publications

View all Judson RL publications in the NIH PubMed Database

Selected Publications:

MicroRNA Ratios Distinguish Melanomas from Nevi. Bastian BC, Hejna M, Joseph NM, Judson-Torres RL, Lang UE, Oldham MC, Shain AH, Shelton SJ, Torres R, Wei ML, Yeh I (2020). J Invest Dermatol, 140(1), 164-173.e7.


The Evolution of Melanoma - Moving beyond Binary Models of Genetic Progression. Judson-Torres RL, Shain AH, Zeng H (2019). (Epub ahead of print) J Invest Dermatol.


Research Techniques Made Simple: Feature Selection for Biomarker Discovery. Judson-Torres RL, Torres R (2019). J Invest Dermatol, 139(10), 2068-2074.e1.


MicroRNA ratios distinguish melanomas from nevi. Journal of Investigative Dermatology. Bastian BC, Hejna M, Joseph NM, Judson-Torres RL, Lang UE, Oldham MC, Shain AH, Shelton SJ, Torres R, Wei ML, Yeh I (2019). Journal of Investigative Dermatology.


Research Techniques Made Simple: Feature Selection for Biomarker Discovery. Judson-Torres RL , Torres R (2019). Journal of Investigative Dermatology.


Evaluation of holographic imaging cytometer holomonitor M4® motility applications. Judson RL, Zhang Y (2018). Cytometry A, 93(11), 1125-1131.


Genomic and transcriptomic analysis reveals incremental disruption of key signaling pathways during melanoma evolution. Bastian BC, Benhamida J, Shain AH, Joseph N, Judson RL, North J, Ruben B, Yeh I, Yu R (2018). Cancer Cell, 34(1), 45-55.


Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation. Bastian BC, Bastian IN, Botton T, Donne M, Jorapur A, Joseph NM, Judson RL, Lang UE, Lin J, McNeal AS, North JP, Pincus L, Ruben BS, Shain AH, Torres R, Zeng H, Zhang Y, Yeh I, Yu R (2018). Cancer Cell , 34(1), 56-68.e9.


Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi. Bastian BC, Cerroni L, Chen X, de la Fouchardière A, Durieux E, Haddad V, Jorapur A, Judson RL, Lang UE, LeBoit PE, McCalmont TH, Pissaloux D, Shain AH, Tee MK, Yeh I, (2017). Nat Commun, 8(1), 644.


High accuracy label-free classification of single-cell kinetic states from holographic cytometry of human melanoma cells. Hejna M, Jorapur A, Judson RL, Song JS (2017). Sci Rep, 7(1), 11943.


CDK1 inhibition targets the p53-NOXA-MCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation. Blelloch R, Creasman KJ, Evason KJ, Goga A, Guo T, Hebrok M, Huskey NE, Judson RL, Momcilovic O, Oakes SA, Pardo D (2015). Stem Cell Reports, 4(3), 374-89.


Two miRNA clusters reveal alternative paths in late-stage reprogramming. Blelloch A, Blelloch R, Judson RL, Krishnakumar R, LaRussa MF, Oldham MC, Parchem RJ, Ye J (2014). Cell Stem Cell, 14(5), 617-31.


MicroRNA-based discovery of barriers to dedifferentiation of fibroblasts to pluripotent stem cells. Blelloch R, Greve TS, Judson RL, Parchem RJ (2013). MicroRNA-based discovery of barriers to dedifferentiation of fibroblasts to pluripotent stem cells. Nat Struct Mol Biol, 20(10), 1227-35.


microRNA control of mouse and human pluripotent stem cell behavior. Blelloch R, Greve TS, Judson RL (2013). Annu Rev cell Dev Biol, 29213-239.


Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Blelloch R, Bucay N, Derynck R, Judson RL, Lamouille S, Liu JY, Subramanyam D (2011). Nat Biotechnol, 29(5), 443-8.


miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Ashton LJ, Balakrishnan A, Blelloch R, Chanthery Y, Chetcuti A, Goga A, Haber M, Hackett CS, Huskey N, Judson RL, L'Etoile N, Lengyel P, Lim L, Marcusson EG, Nguyen A, Norris MD, Phua Y, Preiss T, Shaw A, Sullivan CS, Swarbrick A, Woods SL, Weiss W (2010). Nat Med, 16(10), 1134-40.


Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Blelloch R, Judson RL, Melton C (2010). Nature, 463(7281), 621-6.


Embryonic stem cell-specific microRNAs promote induced pluripotency. Babiarz JE, Blelloch R, Judson RL, Venere M (2009). Nat Biotechnol, 27(5), 459-61.


The GP(Y/F) domain of TF1 integrase multimerizes when present in a fragment, and substitutions in this domain reduce enzymatic activity of the full-length protein. Chatterjee AG, Ebina H, Judson RL, Levin HL (2008). J Biol Chem, 283(23), 15965-74.


The self primer of the long terminal repeat retrotransposon Tf1 is not removed during reverse transcription. Atwood-Moore A, Judson RL, Levin HL, Yan K, (2006). J Virol, 80(16), 8267-70.